Modality
Vaccine
MOA
CAR-T CD19
Target
TIGIT
Pathway
DDR
AsthmaADPKDMDD
Development Pipeline
Preclinical
Apr 2022
→ Jul 2030
PreclinicalCurrent
NCT04218959
2,385 pts·ADPKD
2023-11→TBD·Active
NCT06917086
945 pts·ADPKD
2022-04→2030-07·Not yet recruiting
3,330 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-124.3y awayInterim· ADPKD
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2030-07-12 · 4.3y away
ADPKD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04218959 | Preclinical | ADPKD | Active | 2385 | 6MWD |
| NCT06917086 | Preclinical | ADPKD | Not yet recr... | 945 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT |